Recent Business Highlights:
- The European Medicines Agency confirmed that they are in overall agreement with our Phase III development plan for OGX-011 in patients with CRPC. - Two peer-reviewed manuscripts were published that further explain the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor of clusterin such as OGX-011, to enhance the effectiveness of cancer therapies. One of the co-authors to these manuscripts, Dr. Martin Gleave, is also the Company's Chief Scientific Advisor.
- Grant funding was secured for a randomized, investigator-sponsored Phase II trial of OGX-427 when administered as a monotherapy to patients with CRPC. - Two peer-reviewed manuscripts were published that provide further insight into the mechanism of action of heat shock protein 27 (Hsp27). OGX-427 is designed to reduce levels of Hsp27. - Final results from a Phase 1 study involving OGX-427 will be presented as part of the Scientific Program in a General Poster Session with discussion at the ASCO 2010 Annual Meeting. These final data, including results combining OGX-427 with docetaxel, will update preliminary data that was featured in an oral presentation at the ASCO 2009 meeting.
- Dr. Jack Goldstein and Ms. H. Stewart Parker were appointed to the board of directors. Dr. Goldstein joins the board as chairman. In addition, Dr. Martin Mattingly has agreed to stand for election at the Company's upcoming
|SOURCE OncoGenex Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved